Publicação
Targeting bone metastases in prostate cancer: improving clinical outcome
| dc.contributor.author | Body, Jean-Jacques | |
| dc.contributor.author | Casimiro, Sandra | |
| dc.contributor.author | Costa, Luis | |
| dc.date.accessioned | 2022-09-23T12:49:59Z | |
| dc.date.available | 2022-09-23T12:49:59Z | |
| dc.date.issued | 2015 | |
| dc.description | © 2015 Macmillan Publishers Limited. All rights reserved | pt_PT |
| dc.description.abstract | Bone metastases develop in most patients with metastatic castration-resistant prostate cancer (mCRPC). They affect the structural integrity of bone, manifesting as pain and skeletal-related events (SREs), and are the primary cause of patient disability, reduced quality of life (QOL) and death. Understanding the pathophysiology of bone metastases resulted in the development of agents that improve clinical outcome, suggesting that managing both the systemic disease and associated bone events is important. Historically, the treatment of CRPC bone metastases with early radiopharmaceuticals and external beam radiation therapy was largely supportive; however, now, zoledronic acid and denosumab are integral to the therapeutic strategy for mCRPC. These agents substantially reduce skeletal morbidity and improve patient QOL. Radium-223 dichloride is the first bone-targeting agent to show improved survival and reduced pain and symptomatic skeletal events in patients with mCRPC without visceral disease. Five other systemic agents are currently approved for use in mCRPC based on their ability to improve survival. These include the cytotoxic drugs docetaxel and cabazitaxel, the hormone-based therapies, abiraterone and enzalutamide, and the immunotherapeutic vaccine sipuleucel-T. Abiraterone and enzalutamide are able to reduce SREs and improve survival in this setting. Novel agents targeting tumour and bone cells are under clinical development. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Nat Rev Urol. 2015 Jun;12(6):340-56 | pt_PT |
| dc.identifier.doi | 10.1038/nrurol.2015.90 | pt_PT |
| dc.identifier.eissn | 1759-4820 | |
| dc.identifier.issn | 1759-4812 | |
| dc.identifier.uri | http://hdl.handle.net/10451/54560 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Springer Nature | pt_PT |
| dc.relation.publisherversion | https://www.nature.com/nrurol/ | pt_PT |
| dc.title | Targeting bone metastases in prostate cancer: improving clinical outcome | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 356 | pt_PT |
| oaire.citation.issue | 6 | pt_PT |
| oaire.citation.startPage | 340 | pt_PT |
| oaire.citation.title | Nature Reviews Urology | pt_PT |
| oaire.citation.volume | 12 | pt_PT |
| person.familyName | Cara de Anjo Casimiro | |
| person.familyName | Costa | |
| person.givenName | Sandra Cristina | |
| person.givenName | Luis | |
| person.identifier.ciencia-id | 0F12-5181-0B22 | |
| person.identifier.ciencia-id | 041E-4ADE-FB64 | |
| person.identifier.orcid | 0000-0002-6917-4477 | |
| person.identifier.orcid | 0000-0002-4782-7318 | |
| person.identifier.scopus-author-id | 14043403400 | |
| rcaap.rights | restrictedAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | fd665de1-a7e6-4638-94c3-ecc645f84607 | |
| relation.isAuthorOfPublication | 8a2ab4c6-ba86-4433-b4b7-6256d81890e5 | |
| relation.isAuthorOfPublication.latestForDiscovery | fd665de1-a7e6-4638-94c3-ecc645f84607 |